No Data
No Data
Telix Pharmaceuticals Launches $200 Million US IPO
Telix Pharmaceuticals (ASX:TLX) has launched its $200 million initial public offering on the Nasdaq, according to a Thursday Australian bourse filing. The company expects to grant the underwriters a 3
Telix Kicks off $300M NASDAQ IPO Offer, Backed by Morgan Stanley
Morgan Stanley and Jefferies are among the managers overseeing Telix Pharma’s (ASX:TLX) freshly commenced US IPO process to raise $300M and list on the NASDAQ.
3 High-flying ASX Shares That Could Keep on Climbing
Over the last 12 months, the ASX 200 index has risen over 7%. While this is a decent return, it pales in comparison to some of the returns that have been recorded by ASX shares.
Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$16.62 From AU$13.94, Keeps at Buy
Telix Pharmaceuticals (ASX:TLX) has an average rating of buy and price targets ranging from AU$13.90 to AU$26, according to analysts polled by CapitalIQ. Price (AUD): $18.32, Change: $+0.17, Percent C
Sell in May and Go Away? Not for These Top 3 ASX 200 Stocks!
Three S&P/ASX 200 Index (ASX: XJO) stocks did more than their fair share of the heavy lifting in May.
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF), CSL (OtherCMXHF) and Telix Pharmaceuticals Ltd. (OtherTLPPF)
No Data